arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Xencor Inc

XNCR
$25.14 ▲ +0.11 (+0.44%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
56 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

Xencor Inc faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $1.9B
Dividend Yield
Revenue Growth 17.5%
Op. Margin -72.4%
ROIC -6.3%
FCF / Share $-0.74
Trailing P/E
Price / Book 3.7x
FCF Yield
Debt / Equity 0.15
info Valuation on last close. End-of-day price, Sep 22, 2026.

56-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$51.22M
↑ +17.5%
Net Income Profit after all expenses
$-21.73M
↑ +29.5%
Operating Margin Operating profit as % of sales
-72.4%
↑ +61.9% 1th
FCF / Share Free cash flow per share
$-0.74
↑ +18.3%
Long-Term Debt Long-term obligations
$77.54M
↓ -5.6%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
2
Returns
31
Financial Health
40
Cash Quality
80

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 56 quarters